Form 4: Nexalin CEO Mark White Granted 1M Stock Options

Nexalin Technology CEO Mark White was granted 1,000,000 stock options with an exercise price of $0.83, exercisable immediately.

Summary

• Mark White, CEO and Director of Nexalin Technology, Inc. (NXL), acquired 1,000,000 stock options.
• The options have an exercise price of $0.83 per share.
• They are exercisable as of December 19, 2025, and expire on December 19, 2030.
• The grant was made under the 2023 Equity Incentive Plan.
• The grant is subject to shareholder approval to increase the plan limit under NASDAQ rules.
• Following this transaction, Mark White beneficially owns 2,387,024 derivative securities.

Sentiment

Score: 7

Explanation: The grant of a significant number of stock options to the CEO is generally viewed positively as it aligns management's interests with long-term shareholder value. The immediate exercisability is also a positive. The only minor negative is the contingency on shareholder approval for the plan limit increase.

Positives

• CEO Mark White received a significant grant of 1,000,000 stock options, aligning his interests with shareholder value creation.
• The options are immediately exercisable as of the transaction date, providing direct incentive.

Negatives

• The stock option grant is subject to shareholder approval to increase the 2023 Equity Incentive Plan limit, indicating a potential hurdle or future dilution if approved.

Risks

• The stock option grant is subject to shareholder approval to increase the 2023 Equity Incentive Plan limit under NASDAQ rules, which could delay or prevent the full realization of the grant if not approved.
• Potential dilution for existing shareholders if the plan limit is increased and more options/shares are issued in the future.

Future Outlook

The grant of stock options to the CEO suggests a long-term incentive structure, aligning management's future performance with the company's stock appreciation, contingent on shareholder approval for the plan limit increase.

Management Comments

• Granted under the 2023 Equity Incentive Plan, subject to Shareholder Approval to increase the Plan limit under NASDAQ Rules.

Industry Context

This is a standard executive compensation practice in publicly traded companies, aiming to incentivize leadership through equity ownership. The need for shareholder approval for the plan limit increase is a common governance requirement, especially for smaller or growth-stage companies, to ensure compliance with exchange rules and maintain investor confidence.

Comparison to Industry Standards

• Granting stock options to key executives like the CEO is a common practice across industries to align management incentives with shareholder interests, similar to practices at companies like XYZ Corp. or ABC Inc. in the technology sector.
• An exercise price of $0.83, if at or above the market price on the grant date, indicates a performance-based incentive, a common feature in executive compensation packages.
• The requirement for shareholder approval to increase the equity incentive plan limit is a standard corporate governance measure, ensuring transparency and investor oversight, comparable to similar requirements seen in other NASDAQ-listed companies when expanding their equity compensation pools.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased alignment of CEO's interests with shareholder value. Potential for future dilution if the plan limit is increased and more equity is issued.
• Management/Employees: The CEO receives a significant equity incentive, potentially boosting morale and retention for key leadership.

Next Steps

• Nexalin Technology, Inc. will need to seek shareholder approval to increase the 2023 Equity Incentive Plan limit under NASDAQ rules.

Key Dates

Recommendation

The Form 4 filing reports an insider transaction, specifically a stock option grant to the CEO. While this aligns management's interests with shareholders, it does not provide new fundamental information about the company's operational performance or financial health that would warrant a change in investment thesis. The grant is contingent on shareholder approval, which introduces a minor uncertainty. Therefore, a 'hold' recommendation is appropriate, awaiting further operational updates or the outcome of the shareholder vote.

Keywords

Nexalin Technology, NXL, Mark White, Stock Options, CEO, Director, Equity Incentive Plan, Form 4, Insider Trading, Executive Compensation